BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007;143:306-308. [PMID: 17372094 DOI: 10.1001/archderm.143.3.306] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Hobbs MM, Ortega-Loayza AG. Pyoderma gangrenosum: From historical perspectives to emerging investigations. Int Wound J 2020;17:1255-65. [PMID: 32378319 DOI: 10.1111/iwj.13389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, Soto-Escribano P, Calvo-Moya M, Ginard-Vicens D, Chaparro-Sánchez M. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58:2949-2954. [PMID: 23828140 DOI: 10.1007/s10620-013-2762-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
3 Li J, Kelly R. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. Journal of the American Academy of Dermatology 2013;69:565-9. [DOI: 10.1016/j.jaad.2013.05.028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
4 Zold E, Nagy A, Devenyi K, Zeher M, Barta Z. Successful use of adalimumab for treating fistulizing Crohn’s disease with pyoderma gangrenosum: Two birds with one stone. World J Gastroenterol. 2009;15:2293-2295. [PMID: 19437575 DOI: 10.3748/wjg.15.2293] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
5 Prajapati V, Man J, Brassard A. Pyoderma gangrenosum: common pitfalls in management and a stepwise, evidence-based, therapeutic approach. J Cutan Med Surg 2009;13 Suppl 1:S2-11. [PMID: 19480746 DOI: 10.2310/7750.2009.00002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
6 Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. 2017;18:355-372. [PMID: 28224502 DOI: 10.1007/s40257-017-0251-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 57] [Article Influence: 32.7] [Reference Citation Analysis]
7 Mckenzie F, Arthur M, Ortega-loayza AG. Pyoderma Gangrenosum: What Do We Know Now? Curr Derm Rep 2018;7:147-57. [DOI: 10.1007/s13671-018-0224-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
8 Hinterberger L, Müller CS, Vogt T, Pföhler C. Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatol Ther (Heidelb) 2012;2:6. [PMID: 23205329 DOI: 10.1007/s13555-012-0006-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yamasaki K, Yamanaka K, Zhao Y, Iwano S, Takei K, Suzuki K, Yamamoto T. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty-six-week phase 3 open-label study. J Dermatol 2020;47:1383-90. [PMID: 32804433 DOI: 10.1111/1346-8138.15533] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Andrisani G, Guidi L, Papa A, Potenza A, Cervelli D, Armuzzi A. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery. Journal of Crohn's and Colitis 2013;7:421-6. [DOI: 10.1016/j.crohns.2012.07.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
11 Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J 2019;16:511-21. [PMID: 30604927 DOI: 10.1111/iwj.13067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
12 Weedon D. The vasculopathic reaction pattern. Weedon's Skin Pathology. Elsevier; 2010. pp. 195-244.e49. [DOI: 10.1016/b978-0-7020-3485-5.00009-7] [Cited by in Crossref: 11] [Article Influence: 1.0] [Reference Citation Analysis]
13 Dabade TS, Davis MDP. Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome): Neutrophilic dermatoses. Dermatologic Therapy 2011;24:273-84. [DOI: 10.1111/j.1529-8019.2011.01403.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
14 Sockolov ME, Alikhan A, Zargari O. Non-psoriatic dermatologic uses of monoclonal antibody therapy. Journal of Dermatological Treatment 2009;20:319-27. [DOI: 10.3109/09546630902936778] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
15 McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat 2019;30:264-76. [PMID: 30051737 DOI: 10.1080/09546634.2018.1506083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
16 Traczewski P, Rudnicka L. Adalimumab in dermatology. Br J Clin Pharmacol 2008;66:618-25. [PMID: 18754844 DOI: 10.1111/j.1365-2125.2008.03263.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
17 Díaz-ley B, Guhl G, Fernández-herrera J. Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab. Actas Dermo-Sifiliográficas 2007;98:657-78. [DOI: 10.1016/s0001-7310(07)70159-x] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
18 Bonamigo RR, Razera F, Olm GS. Dermatoses neutrofílicas: parte I. An Bras Dermatol 2011;86:11-27. [DOI: 10.1590/s0365-05962011000100002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
19 Protopsaltis I, Angelidi A, Milionis H, Katsantonis I, Gavra P, Zizi-sermpetzoglou A, Perimeni D, Paschalidis N. More Than Skin Deep. The American Journal of Medicine 2009;122:830-2. [DOI: 10.1016/j.amjmed.2009.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199-1201. [PMID: 19673875 DOI: 10.1111/j.1365-2133.2009.09404.x] [Cited by in Crossref: 151] [Cited by in F6Publishing: 113] [Article Influence: 12.6] [Reference Citation Analysis]
21 Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646-654. [PMID: 20227580 DOI: 10.1016/j.jaad.2009.05.030] [Cited by in Crossref: 134] [Cited by in F6Publishing: 90] [Article Influence: 12.2] [Reference Citation Analysis]
22 Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol 2007;157:1274-5. [PMID: 17916198 DOI: 10.1111/j.1365-2133.2007.08212.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
23 Havnaer A, Han G. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment. Am J Clin Dermatol 2019;20:539-64. [DOI: 10.1007/s40257-019-00440-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
24 Wollina U, Haroske G. Pyoderma gangraenosum. Current Opinion in Rheumatology 2011;23:50-6. [DOI: 10.1097/bor.0b013e328341152f] [Cited by in Crossref: 57] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
25 Eisendle K, Thuile T, Deluca J, Pichler M. Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases. Adv Wound Care (New Rochelle) 2020;9:405-25. [PMID: 32320362 DOI: 10.1089/wound.2020.1160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
26 Garcovich S, De Simone C, Berti E, Marzano AV. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol 2017;10:1119-28. [PMID: 28715916 DOI: 10.1080/17512433.2017.1356719] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
27 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]